However, it’s worth noting that 25.5% of the patients were ER+/PR− IBC in our study and this proportion is much higher than that of the whole breast cancer population, which may partly explain the worse outcome of IBC. This evidence concerns the gene ESR1 and inflammatory breast carcinoma.